Trials / Completed
CompletedNCT01370070
MK-2206 in Recurrent Nasopharyngeal Carcinoma
Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the activity and safety of MK-2206 in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-2206 | 200mg weekly repeated q 28 days |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2016-12-01
- Completion
- 2017-01-01
- First posted
- 2011-06-09
- Last updated
- 2017-01-13
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT01370070. Inclusion in this directory is not an endorsement.